VivoSeq
Oncology

Patients With Solid Tumors

0

Pipeline Programs↗

71

Active Trials↗

98

Companies Involved↗

Patients With Solid Tumors is an early-stage landscape with 0 programs across 98 companies. The most active players are Pfizer, Roche, Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

39/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalGSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

315

clinical trials

Completed177 · 56%
Recruiting43 · 14%
Terminated31 · 10%
Active, not recruiting23 · 7%
Unknown status21 · 7%
Withdrawn10 · 3%
Other10 · 3%

Clinical Trials

Trial Activity

315 trials

A Study of TYK-00540 in Adult Patients With Solid Tumors
Recruiting·TTYK Medicines, Inc·Phase 1·NCT06246071·156 enrolled
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Recruiting·EEpkin·Phase 1·NCT06789172·166 enrolled
A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors
Recruiting·CCellSight Technologies, Inc.·Phase 2·NCT04260256·40 enrolled
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Recruiting·CClasp Therapeutics, Inc.·Phase 1·NCT06778863·90 enrolled
PET-imaging of Two Vartumabs in Patients With Solid Tumors
Recruiting·VVar2 Pharmaceuticals·Phase 1·NCT06645808·32 enrolled
A Study of VET3-TGI in Patients With Solid Tumors
Recruiting·KKaliVir Immunotherapeutics·Phase 1·NCT06444815·60 enrolled
Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells
Recruiting·UUNICANCER·Phase 2·NCT06653777·40 enrolled
Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.
Recruiting·UUNICANCER·Phase 2·NCT07192068·105 enrolled
A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation
Recruiting·Changchun GeneScience Pharmaceutical Co., Ltd. logoChangchun GeneScience Pharmaceutical Co., Ltd.·Phase 1·NCT06908434·82 enrolled
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors
Recruiting·SShanghai Virogin Biotech Co., Ltd.·Phase 1·NCT05477849·30 enrolled
Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors
Recruiting·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT07258160·127 enrolled
Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
Recruiting·—·Phase 1·NCT02446431·20 enrolled
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors
Recruiting·SShanghai Virogin Biotech Co., Ltd.·Phase 1·NCT07262164·30 enrolled
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Recruiting·RRise Therapeutics LLC·Phase 1·NCT06398418·33 enrolled
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
Recruiting·PPure Biologics S.A.·Phase 1·NCT06700070·12 enrolled
Page 1 of 21

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)